Vedolizumab as a first-choice biological treatment of Crohn’s disease in a patient with paraganglioma of the nervous system
Gastroenterology Review · 2026 · 21 (1) · 108-110
DOI: 10.5114/pg.2026.160317 ↗Kurz gefasst
Leserbrief in der Zeitschrift Gastroenterology Review, 2026. Verfasst von Patrycja Szałwińska und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Digestive Tract Diseases, Medical University of Lodz, Poland. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Paragangliomas are rare, usually benign neuroendocrine tumours originating from the paraganglionic bodies of the parasympathetic and sympathetic nervous system, most often located at the bifurcation of the common carotid artery. Inflammatory
Autor:innen und Institutionen
- Department of Digestive Tract Diseases, Medical University of Lodz, Poland.
- Department of Digestive Tract Diseases, Faculty of Medicine, Medical University of Lodz, Poland.
Zitieren
APA
Szałwińska, P., & Ewa Malecka-, W. (2026). Vedolizumab as a first-choice biological treatment of Crohn’s disease in a patient with paraganglioma of the nervous system. Gastroenterology Review, 21(1), 108-110. https://doi.org/10.5114/pg.2026.160317
Vancouver
Szałwińska P, Ewa Malecka- W. Vedolizumab as a first-choice biological treatment of Crohn’s disease in a patient with paraganglioma of the nervous system. Gastroenterology Review. 2026;21(1):108-110. doi:10.5114/pg.2026.160317
BibTeX
@article{Szawiska2026,
author = {Szałwińska, Patrycja and Ewa Malecka-, Wojciesko},
title = {Vedolizumab as a first-choice biological treatment of Crohn’s disease in a patient with paraganglioma of the nervous system},
journal = {Gastroenterology Review},
year = {2026},
volume = {21},
number = {1},
pages = {108--110},
doi = {10.5114/pg.2026.160317}
}
EUVIMED